by | May 9, 2024 | Publications
Hematol Transfus Cell Ther. 2024 Apr 15:S2531-1379(24)00068-3. doi: 10.1016/j.htct.2024.02.024. Online ahead of print. NO ABSTRACT PMID:38719721 | DOI:10.1016/j.htct.2024.02.024
by | May 9, 2024 | Publications
BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0. ABSTRACT BACKGROUND: Impaired immune response in multiple myeloma renders the patients vulnerable to infections, such as COVID-19, and may cause worse response to vaccines. Researchers should analyze...
by | May 9, 2024 | Publications
Front Immunol. 2024 Apr 19;15:1389018. doi: 10.3389/fimmu.2024.1389018. eCollection 2024. ABSTRACT INTRODUCTION: Multiple myeloma (MM) remains incurable, despite the advent of chimeric antigen receptor (CAR)-T cell therapy. This unfulfilled potential can be attributed...
by | May 9, 2024 | Publications
Ther Adv Hematol. 2024 May 7;15:20406207241245194. doi: 10.1177/20406207241245194. eCollection 2024. ABSTRACT Treatment of multiple myeloma (MM) has evolved remarkably over the past few decades. Autologous stem cell transplantation, as well as proteasome inhibitors,...
by | May 9, 2024 | Publications
Front Health Serv. 2024 Apr 24;4:1354760. doi: 10.3389/frhs.2024.1354760. eCollection 2024. ABSTRACT BACKGROUND: Advances in multiple myeloma (MM) treatment have shifted the therapeutic landscape. Understanding patients’ perspectives can assist physicians in...
by | May 9, 2024 | Publications
Eur J Haematol. 2024 May 9. doi: 10.1111/ejh.14222. Online ahead of print. ABSTRACT OBJECTIVES: The aim of this noninterventional, retrospective ALFA study was to describe belantamab mafodotin effectiveness and safety in patients with relapsed/refractory multiple...
